Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
VANCOUVER, British Columbia , Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that
02.14.2024Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
VANCOUVER, British Columbia , Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced the
02.08.2024Zymeworks Announces Participation in Upcoming Investor Conferences
VANCOUVER, British Columbia , Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, today announced that
01.31.2024Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025
Company well-positioned for further progress and broadening of R&D pipeline Cash resources of approximately $455 million as of December 31, 2023 (unaudited) Expected cash runway, including proceeds from recent private placement, into 2H 2027 Top-line data readout from the Phase 3 trial evaluating
01.04.2024Zymeworks Announces Additional Leadership Appointments
Dr. Jeffrey Smith named Executive Vice President and Chief Medical Officer Dr. John Fann promoted to Senior VP, Process Sciences Seven new Vice Presidents appointed, underscoring commitment to leadership development VANCOUVER, British Columbia , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc.
01.04.2024